Beyer, K. (2006). Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathologica, 112, 237–251.
Blennow, K., Wallin, A. and Hager, O. (1993). Low frequency of post-lumbar puncture headache in demented patients. Acta Neurologica Scandinavica, 88, 221–223.
Brookes, A. J. and St Clair, D. (1994). Synuclein proteins and Alzheimer's disease. Trends in Neurosciences, 17, 404–405.
Chen, X., de Silva, H. A., Pettenati, M. J.
et al. (1995). The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis. Genomics, 26, 425–427.
Culvenor, J. G., McLean, C. A., Cutt, S.
et al. (1999). Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. The American Journal of Pathology, 155, 1173–1181.
Egger, M., Davey Smith, G., Schneider, M. and Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal, 315, 629–634.
Emre, M. (2007). Treatment of dementia associated with Parkinson's disease. Parkinsonism and Related Disorders, 13, 457–461.
Esposito, A., Dohm, C. P., Kermer, P., Bahr, M. and Wouters, F. S. (2007). Alpha-synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiology of Disease, 26, 521–531.
Formichi, P., Battisti, C., Radi, E. and Federico, A. (2006). Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. Journal of Cellular Physiology, 208, 39–46.
George, J. M., Jin, H., Woods, W. S. and Clayton, D. F. (1995). Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron, 15, 361–372.
Goedert, M. (1999). Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 354, 1101–1118.
et al. (2010). DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain, 133, 713–726.
Irizarry, M. C.
et al. (1996). Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. Journal of Neuropathology and Experimental Neurology, 55, 889–895.
Irwin, D. J., White, M. T., Toledo, J. B.
et al. (2012). Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 72, 587–598.
et al. (1995). The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron, 14, 467–475.
Jakes, R., Spillantini, M. G. and Goedert, M. (1994). Identification of two distinct synucleins from human brain. FEBS Letters, 345, 27–32.
Jellinger, K. A. and Attems, J. (2008). Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathologica, 115, 427–436.
Jicha, G. A., Abner, E. L., Schmitt, F. A.
et al. (2012). Preclinical AD workgroup staging: pathological correlates and potential challenges. Neurobiology of Aging, 33, 622, e621–622.e616.
Kakimura, J., Kitamura, Y., Takata, K., Kohno, Y., Nomura, Y. and Taniguchi, T. (2001). Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. European Journal of Pharmacology, 417, 59–67.
Kapaki, E., Paraskevas, G. P., Emmanouilidou, E. and Vekrellis, K. (2013). The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease. PloS One, 8, e81654.
et al. (2010). Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 81, 608–610.
Kholodilov, N. G.
et al. (1999). Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. Journal of Neurochemistry, 73, 2586–2599.
Lavedan, C. (1998). The synuclein family. Genome Research, 8, 871–880.
Marti, M. J., Tolosa, E. and Campdelacreu, J. (2003). Clinical overview of the synucleinopathies. Movement Disorders: Official Journal of the Movement Disorder Society, 18
(Suppl. 6), S21–S27.
McKeith, I. (2004). Dementia with Lewy bodies. Dialogues in Clinical Neuroscience, 6, 333–341.
et al. (1998). Mitochondrial dysfunction in Parkinson's disease. Annals of Neurology, 44, S99–S109.
et al. (2005). Tau protein, abeta 42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dementia and Geriatric Cognitive Disorders, 19, 164–170.
et al. (2008). Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Experimental Neurology, 213, 315–325.
et al. (2011). Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurology, 10, 230–240.
et al. (2009). CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Research, 1251, 1–6.
et al. (1999). Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 19, 5782–5791.
Parnetti, L., Chiasserini, D., Bellomo, G.
et al. (2011). Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Movement Disorders: Official Journal of the Movement Disorder Society, 26, 1428–1435.
Parnetti, L., Lanari, A., Amici, S., Gallai, V., Vanmechelen, E. and Hulstaert, F. (2001). Phospho-tau international study group. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies, phospho-tau international study group. Journal of the Neurological Sciences, 22, 77–78.
Petersen, R. C.
et al. (2009). Mild cognitive impairment: ten years later. Archives of Neurology, 66, 1447–1455.
Santacruz, K. S. and Swagerty, D. (2001). Early diagnosis of dementia. American Family Physician, 63, 703–714.
et al. (2011). Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology, 69, 570–580.
Souza, J. M., Giasson, B. I., Lee, V. M. and Ischiropoulos, H. (2000). Chaperone-like activity of synucleins. FEBS Letters, 474, 116–119.
Spies, P. E., Melis, R. J., Sjogren, M. J., Rikkert, M. G. and Verbeek, M. M. (2009). Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. Journal of Alzheimer's Disease, 16, 363–369.
Spillantini, M. G., Divane, A. and Goedert, M. (1995). Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics, 27, 379–381.
Stefanis, L., Kholodilov, N., Rideout, H. J., Burke, R. E. and Greene, L. A. (2001). Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. Journal of Neurochemistry, 76, 1165–1176.
Stewart, T., Liu, C. Q., Carmen, G.
et al. (2014). Cerebrospinal fluida-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. The American Journal of Pathology, 184, 966–975.
Tang, W., Huang, Q., Wang, Y., Wang, Z. Y. and Yao, Y. Y. (2014a). Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. Journal of Neural Transmission, 121, 1541–1553.
Tang, W., Huang, Q., Wang, Y., Wang, Z. Y. and Yao, Y. Y. (2014b). Does CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies. Journal of the Neurological Sciences, 345, 26–36.
Tateno, F., Sakakibara, R., Kawai, T., Kishi, M. and Murano, T. (2012). Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Disease and Associated Disorders, 26, 213–216.
Tokuda, T., Qureshi, M. M., Ardah, M. T.
et al. (2010). Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology, 75, 1766–1772.
Ueda, K., Fukushima, H., Masliah, E.
et al. (1993). Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 90, 11282–11286.
van der Putten, H., Wiederhold, K. H., Probst, A.
et al. (2000). Neuropathology in mice expressing human alpha-synuclein. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience, 20, 6021–6029.
Wennstrom, M., Londos, E., Minthon, L. and Nielsen, H. M. (2012). Altered CSF orexin and alpha-synuclein levels in dementia patients. Journal of Alzheimer's disease, 29, 125–132.